Related Experiment Video
Updated: Aug 13, 2026
09:15
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Comparative studies on nicotinic acid derivatives as hypolipoproteinemic agents
1Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Karachi, Karachi-75270, Pakistan.
Pakistan Journal of Pharmaceutical Sciences
|January 18, 2006
Summary
New nicotinic acid derivatives, T1 and T2, show promise in lowering blood lipids by reducing very low-density lipoprotein (VLDL) production. These compounds may offer a safer alternative to existing lipid-lowering drugs.
Area of Science:
- Pharmacology
- Medicinal Chemistry
- Biochemistry
Background:
- Nicotinic acid is a lipid-lowering agent, but clinical use is limited by side effects.
- New nicotinic acid derivatives are synthesized to mitigate adverse effects.
- Antilipoproteinemic effects of novel compounds are investigated.
Purpose of the Study:
- To evaluate the hypolipoproteinemic effects of two novel nicotinic acid derivatives: 3-methoxy phenacyl nicotinium bromide (T1) and 2-methoxy phenacyl nicotinium bromide (T2).
- To compare the efficacy of T1 and T2 with standard drugs like aspirin and clofibrate.
Main Methods:
- Synthesis of two new nicotinic acid derivatives, T1 and T2.
- Administration of compounds at 30 mg/day to white male rabbits.
- Comparison of lipid profiles with aspirin and clofibrate as reference standards.
Main Results:
- Both T1 and T2 demonstrated significant hypolipoproteinemic effects in rabbits.
- The compounds likely reduce plasma lipoproteins by inhibiting hepatic very low-density lipoprotein (VLDL) production.
- This mechanism ultimately leads to a reduction in low-density lipoprotein (LDL) levels.
Conclusions:
- The synthesized nicotinic acid derivatives (T1 and T2) possess notable lipid-lowering properties.
- These compounds represent potential therapeutic agents for managing dyslipidemia.
- Further research is warranted to explore their clinical efficacy and safety profile.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:27Bioavailability Study Design: Absolute Versus Relative Bioavailability
Bioavailability is a crucial pharmacokinetic parameter that quantifies the proportion of an administered drug that reaches the systemic circulation and is available for therapeutic action. Regulatory agencies mandate the assessment of bioavailability, typically measured as the area under the drug plasma concentration-versus-time curve (AUC), to ensure the efficacy and safety of pharmaceutical products. These evaluations are categorized as absolute and relative bioavailability studies.Absolute...
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
01:06Lipid Digestion
Lipids are large molecules that are generally not water-soluble. Since most of the digestive enzymes in the human body are water-based, there are specific steps the body must take to break down lipids and make them available for use.